Tohru Hashida

1.8k total citations
90 papers, 1.3k citations indexed

About

Tohru Hashida is a scholar working on Surgery, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Tohru Hashida has authored 90 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Surgery, 20 papers in Oncology and 14 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Tohru Hashida's work include Safe Handling of Antineoplastic Drugs (13 papers), Pharmacy and Medical Practices (11 papers) and Renal Transplantation Outcomes and Treatments (10 papers). Tohru Hashida is often cited by papers focused on Safe Handling of Antineoplastic Drugs (13 papers), Pharmacy and Medical Practices (11 papers) and Renal Transplantation Outcomes and Treatments (10 papers). Tohru Hashida collaborates with scholars based in Japan, United States and Switzerland. Tohru Hashida's co-authors include Ken‐ichi Inui, Shinji Üemoto, Ikuko Yano, Hiroaki Ikesue, Kōichi Tanaka, Hideyuki Saito, Yukihiro Inomata, Nobuyuki Muroi, Satohiro Masuda and Shigetake Sasayama and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Tohru Hashida

81 papers receiving 1.2k citations

Peers

Tohru Hashida
Timothy R. McGuire United States
H. Iven Germany
Stefan Reuter Germany
Kate Wyburn Australia
Angelo M. de Mattos United States
Stephen J. Rossi United States
M. Arias Spain
Simona Granata Italy
Francesco Marchini Italy
Varvara A. Kirchner United States
Timothy R. McGuire United States
Tohru Hashida
Citations per year, relative to Tohru Hashida Tohru Hashida (= 1×) peers Timothy R. McGuire

Countries citing papers authored by Tohru Hashida

Since Specialization
Citations

This map shows the geographic impact of Tohru Hashida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tohru Hashida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tohru Hashida more than expected).

Fields of papers citing papers by Tohru Hashida

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tohru Hashida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tohru Hashida. The network helps show where Tohru Hashida may publish in the future.

Co-authorship network of co-authors of Tohru Hashida

This figure shows the co-authorship network connecting the top 25 collaborators of Tohru Hashida. A scholar is included among the top collaborators of Tohru Hashida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tohru Hashida. Tohru Hashida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hotta, T, Keizo Fukushima, Kei Irie, et al.. (2024). Effect of Hematopoietic Stem Cell Transplantation Regimen on Tacrolimus Pharmacokinetics. Current Therapeutic Research. 102. 100775–100775.
3.
Hashida, Tohru, et al.. (2023). Usefulness of Institutional Decision Support Protocol for Prescription Queries by Community Pharmacists due to Drug Shortages. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 49(7). 247–253.
4.
Irie, Kei, Nobuhiro Hiramoto, Hiroaki Ikesue, et al.. (2023). Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma. Investigational New Drugs. 41(5). 761–767. 4 indexed citations
5.
Irie, Kei, Nobuyuki Fukui, Hirotoshi Imamura, et al.. (2023). Pharmacokinetics of Temozolomide in a Patient With Glioblastoma Undergoing Hemodialysis: A Short Communication. Therapeutic Drug Monitoring. 45(6). 823–826.
6.
Ikesue, Hiroaki, et al.. (2022). Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib. Cancer Chemotherapy and Pharmacology. 89(6). 833–838. 6 indexed citations
7.
Ikesue, Hiroaki, et al.. (2021). Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. Cancer Chemotherapy and Pharmacology. 87(6). 871–877. 14 indexed citations
8.
9.
Ikesue, Hiroaki, Hideaki Tomita, Nobuyuki Muroi, et al.. (2021). Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Supportive Care in Cancer. 29(8). 4763–4772. 27 indexed citations
10.
Irie, Keiichi, et al.. (2021). PHARMACOKINETICS OF FAVIPIRAVIR IN CRITICALLY ILL PATIENTS WITH COVID-19. Clinical Pharmacology & Therapeutics. 109. 6 indexed citations
11.
Ikesue, Hiroaki, Yoshio Masuda, Nobuyuki Muroi, et al.. (2020). Evaluation of the usefulness of protocol‐based pharmacist‐facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer. Journal of Clinical Pharmacy and Therapeutics. 45(6). 1288–1294. 7 indexed citations
12.
Hasegawa, Shiori, Hiroaki Ikesue, Satoshi Nakao, et al.. (2020). Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiology and Drug Safety. 29(10). 1279–1294. 27 indexed citations
13.
Fujimoto, Ayumi, Keizo Fukushima, Kei Irie, et al.. (2020). Population pharmacokinetics of tacrolimus in umbilical cord blood transplant patients focusing on the variation in red blood cell counts. Journal of Clinical Pharmacy and Therapeutics. 46(1). 190–197. 3 indexed citations
14.
Kubota, Masaru, et al.. (2018). Use of Supplements by Japanese Cancer Patients Receiving Outpatient Cancer Chemotherapy. The Journal of Alternative and Complementary Medicine. 24(9-10). 1003–1006. 4 indexed citations
15.
Ikesue, Hiroaki, Tohru Nagano, & Tohru Hashida. (2018). A Case of Acute Kidney Injury Associated With Dabrafenib and Trametinib Treatment for Metastatic Melanoma. Annals of Pharmacotherapy. 52(10). 1051–1052. 4 indexed citations
16.
Ikesue, Hiroaki, et al.. (2018). Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery. Journal of Pharmaceutical Health Care and Sciences. 4(1). 13–13. 4 indexed citations
17.
Ikesue, Hiroaki, Kazumi Fujita, Hobyung Chung, et al.. (2018). Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis. Journal of Pharmaceutical Health Care and Sciences. 4(1). 17–17. 6 indexed citations
18.
Hashida, Tohru, et al.. (2014). Role of Pharmacists in Introduction of New Drugs for the Minimization of Risk. 16(1). 28–32. 1 indexed citations
19.
Tanaka, Shoji, et al.. (2013). The Evaluation of Comprehensive Countermeasures to Reduce Occupational Exposure to Anticancer Drugs during Preparation and Administration. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 39(12). 700–710. 9 indexed citations
20.
Marui, Akira, et al.. (2007). 生物分解ゼラチンヒドロゲルを用いた塩基性線維芽細胞成長因子の持続遊離による重大な肢虚血患者に対する治療血管新生の新しい方法 第I-IIa試験の最初の報告. Circulation. 71(8). 1181–1186. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy R. McGuire Breakdown of academic impact, for papers by H. Iven Breakdown of academic impact, for papers by Stefan Reuter Breakdown of academic impact, for papers by Kate Wyburn Breakdown of academic impact, for papers by Angelo M. de Mattos Breakdown of academic impact, for papers by Stephen J. Rossi Breakdown of academic impact, for papers by M. Arias Breakdown of academic impact, for papers by Simona Granata Breakdown of academic impact, for papers by Francesco Marchini Breakdown of academic impact, for papers by Varvara A. Kirchner
Rankless by CCL
2026